Back to News
Market Impact: 0.25
Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureCompany Fundamentals
Ligand Pharmaceuticals announced a financing agreement with clinical-stage cell therapy company AvenCell Therapeutics worth up to $47 million. The funding is intended to advance AvenCell's pipeline, including AVC-201 for relapsed/refractory disease, although the article excerpt does not provide further clinical, financial, or milestone terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LGND0.45
More News
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Weekend trading of Nvidia scandal shines light on new financial products